BianoGMP GmbH receives invest­ment cap­i­tal from the Thuringia Start-up Fund (TSF) for the pro­duc­tion of DNA- and RNA-based active agents.

There is still a lack of suf­fi­ciently effec­tive ther­a­pies for a num­ber of seri­ous dis­eases. How­ever, a large num­ber of small com­pa­nies and research groups at uni­ver­si­ties are already work­ing on new, bet­ter active sub­stances for such dis­eases. In recent years, the focus has often been on mol­e­c­u­lar biol­ogy, DNA- and RNA-based active sub­stances, but also on the recently devel­oped “gene scis­sors”. How­ever, before these inno­v­a­tive active sub­stances can be clin­i­cally tested in patient stud­ies, they have to be pro­duced in phar­ma­ceu­ti­cal qual­ity (GMP = “Good Man­u­fac­tur­ing Prac­tice”). “BianoGMP GmbH will estab­lish itself as a part­ner and ser­vice provider for the devel­op­ers of these new, highly potent active sub­stances and pave the way for them to enter the clinic by man­u­fac­tur­ing them in phar­ma­ceu­ti­cal qual­ity,” Ste­fan Jahn, Invest­ment Man­ager at bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t), is convinced.
The BianoGMP team has been work­ing on RNA agents for a long time and devel­oped a new class of patented RNA agents as part of a funded project with Friedrich Schiller Uni­ver­sity in Jena. “Our part­ner com­pany BianoScience GmbH will be among the first clients for whom we pro­duce active sub­stances for clin­i­cal tri­als. How­ever, patients will also ben­e­fit from our ser­vice by gain­ing accel­er­ated access to new, inno­v­a­tive ther­a­pies” says Dr Tobias Pöhlmann, Man­ag­ing Direc­tor of BianoGMP.
Dr. Rolf Gün­ther, sec­ond man­ag­ing direc­tor of BianoGMP, empha­sises the role of the region: “The invest­ment of bm|t, Mit­tel­ständis­che Beteili­gungs­ge­sellschaft Thürin­gen mbH and sev­eral pri­vate investors, the major­ity of whom are based in East­ern Thuringia, allows us to estab­lish a tech­ni­cally sophis­ti­cated and effi­cient pro­duc­tion facil­ity at the Gera air­field. In this way, we can offer the drug devel­op­ers to bring their novel devel­op­ments to the clinic together with us more effi­ciently and faster than before.”

About bm|t

The bm‑t beteili­gungs­man­age­ment thürin­gen gmbh, based in Erfurt, is a sub­sidiary of the Thüringer Auf­baubank and the first address for invest­ments in Thuringia. bm|t cur­rently man­ages eight funds with a total invested vol­ume of around €320 mil­lion, which invest in inno­v­a­tive com­pa­nies in almost all sec­tors and in all phases of com­pany devel­op­ment — both in the start-up and growth phases or in com­pany suc­ces­sion situations.

About MBG

Mit­tel­ständis­che Beteili­gungs­ge­sellschaft Thürin­gen mbH has been estab­lished in Thuringia for 25 years. With well over 100 invest­ments in its port­fo­lio, it suc­cess­fully imple­ments eco­nomic devel­op­ment for start-ups, exist­ing com­pa­nies and successions.

About BianoGMP

The com­pany is a start-up in Gera and is based on foun­da­tions laid in a project of the biotech­nol­ogy start-up offen­sive at Friedrich Schiller Uni­ver­sity Jena, funded by the Fed­eral Min­istry of Edu­ca­tion and Research. BianoGMP pro­duces DNA- and RNA-based active sub­stances under GMP on behalf of drug developers.

Press contacts

BianoGMP GmbH
Dr. Tobias Pöhlmann and Dr. Rolf Günther
Ron­neb­urger Street 74
07546 Gera
Tel: +49 365 77347180
Email: rolf.guenther@bianogmp.com
www.BianoGMP.com

bm‑t par­tic­i­pa­tion man­age­ment thürin­gen gmbh
Ste­fan Jahn and Katrin Uschmann
Gork­istraße 9
99084 Erfurt
Phone: +49 361 7447 601
Fax: +49 361 7447 635